

04-30-02

1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1215)

PATENT

In re Application of: Calzone et al.)
)
Serial No.: 09/724,859)
)
Filed: November 28, 2000)
)
For: Interleukin-1 Receptor)
Antagonist-Like Molecules)
and Uses Thereof)

Before the Examiner: P. M. Mertz

Group Art Unit: 1646

RECEIVED

MAY 03 2002

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:


TRANSMITTAL LETTER

1. We are transmitting herewith the attached papers for the above-described patent application:
Response to Restriction Requirement.
2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner for Patents, Washington D.C. 20231, on April 29, 2002.

Respectfully submitted,

McDonnell Boennchen Hulbert & Berghoff

Dated: April 29, 2002

By: 
Donald L. Zuhn, Ph.D.
Reg. No. 48,710



THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1215)

PATENT

In re Application of: Calzone et al.)

Serial No.: 09/724,859)

Before the Examiner: P. M. Mertz

Filed: November 28, 2000)

Group Art Unit: 1646

For: Interleukin-1 Receptor)
Antagonist-Like Molecules)
and Uses Thereof)

RECEIVED

MAY 03 2002

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

RESPONSE TO RESTRICTION REQUIREMENT MAILED MARCH 27, 2002

Responsive to the Restriction Requirement, mailed March 27, 2002, Applicants elect to prosecute claims 1-8, 10, 11, and 42-46, designated as Group I by the Examiner. The claims of Group I are drawn to a polynucleotide encoding an IL-1 receptor antagonist-like polypeptide, a vector, a host cell, and a process for producing the polypeptide.

Applicants do not believe that any additional fee is required. However, the Commissioner is authorized to charge any deficiency to Deposit Account No. 13-2490. If Examiner Mertz believes it to be helpful, she is invited to contact the undersigned representative by telephone at (312) 913-0001.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: April 29, 2002

By: 

Donald L. Zuhn, Ph.D.

Reg. No. 48,710